These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30357044)

  • 1. Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use.
    Melnick S; Rajagopalan P; Lynn T; Donato A
    J Community Hosp Intern Med Perspect; 2018; 8(5):315-316. PubMed ID: 30357044
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
    Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
    Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
    Danford C; Chan P; Magill SB
    WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
    Turner J; Begum T; Smalligan RD
    J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
    Messana JA; Schwartz SS; Townsend RR
    Vasc Health Risk Manag; 2017; 13():43-54. PubMed ID: 28255241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin-associated diabetic ketoacidosis: a case report.
    Chai PR; Bonney C; Blohm E; Boyer EW; Babu KM
    Toxicol Commun; 2017; 1(1):2-5. PubMed ID: 29978156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels.
    Vadi S; Agarwal M
    Indian J Crit Care Med; 2017 Nov; 21(11):793-795. PubMed ID: 29279644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
    Nyirjesy P; Sobel JD; Fung A; Mayer C; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2014 Jun; 30(6):1109-19. PubMed ID: 24517339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged diabetic ketoacidosis associated with canagliflozin.
    Sloan G; Kakoudaki T; Ranjan N
    Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29899991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors.
    Mintz ML
    J Fam Pract; 2016 Dec; 65(12 Suppl):. PubMed ID: 28149983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy.
    Minze MG; Koffarnus RL; Bailey TA; Diec S; Edwards KL
    Expert Rev Endocrinol Metab; 2015 Nov; 10(6):645-661. PubMed ID: 30289035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes.
    Mikhail N
    World J Diabetes; 2014 Dec; 5(6):854-9. PubMed ID: 25512787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report.
    Earle M; Ault B; Bonney C
    Clin Pract Cases Emerg Med; 2020 May; 4(2):185-188. PubMed ID: 32426668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.